These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 12621983)

  • 21. Risk of thromboembolism and bleeding after general surgery in patients with atrial fibrillation.
    Vink R; Rienstra M; van Dongen CJ; Levi M; Büller HR; Crijns HJ; van Gelder IC
    Am J Cardiol; 2005 Sep; 96(6):822-4. PubMed ID: 16169369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation.
    Rockson SG; Albers GW
    J Am Coll Cardiol; 2004 Mar; 43(6):929-35. PubMed ID: 15028346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
    Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Thromboembolic risk in atrial fibrillation: new clinical perspectives].
    Villani GQ; Andreoli AM; Villani M; Capucci A
    G Ital Cardiol (Rome); 2008 Oct; 9(10 Suppl 1):22S-26S. PubMed ID: 19195302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibiotic treatment in atrial fibrillation].
    Halinen MO
    Duodecim; 1989; 105(19):1582-9. PubMed ID: 2680449
    [No Abstract]   [Full Text] [Related]  

  • 27. The need for new oral anticoagulants in clinical practice.
    Hylek EM
    J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):605-9. PubMed ID: 19571764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stroke prevention in hospitalized patients with atrial fibrillation: a population-based study.
    Nagpal S; Anderson D; Putnam W; Flowerdew G; Gardner M; Cox J
    Can J Clin Pharmacol; 2003; 10(4):197-201. PubMed ID: 14712325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Consensus on antithrombotic prophylaxis of vascular events in patients with manifested atherosclerotic vascular disease].
    Schipper JP
    Ned Tijdschr Geneeskd; 1998 Mar; 142(13):736-7. PubMed ID: 9623149
    [No Abstract]   [Full Text] [Related]  

  • 30. Managing anticoagulated atrial fibrillation patients undergoing endoscopy.
    Gorard DA
    Gut; 2009 Mar; 58(3):468; author reply 469. PubMed ID: 19211861
    [No Abstract]   [Full Text] [Related]  

  • 31. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis.
    Lip GY
    Thromb Haemost; 2008 Jul; 100(1):11-3. PubMed ID: 18612530
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardioembolic events in young patients: beyond the heart.
    Martínez-Quintana E; Rodríguez-González F
    Pneumologia; 2015; 64(3):63. PubMed ID: 26738375
    [No Abstract]   [Full Text] [Related]  

  • 33. Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation.
    Kim MH; Decena BF; Bruckman D; Eagle KA
    Am Heart J; 2003 Apr; 145(4):665-9. PubMed ID: 12679763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
    Själander A; Wallentin L; Rosenqvist M; Svensson P
    Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
    [No Abstract]   [Full Text] [Related]  

  • 35. Atrial fibrillation and coagulation: who and when?
    Fitzmaurice D
    Blood Rev; 2009 Nov; 23(6):241-4. PubMed ID: 19709791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ablation for atrial fibrillation: can we decrease thromboembolism without increasing the risk for bleeding?
    Asirvatham SJ
    Circulation; 2007 Nov; 116(22):2517-9. PubMed ID: 18040036
    [No Abstract]   [Full Text] [Related]  

  • 37. A promising advance in anticoagulant therapy for patients with atrial fibrillation.
    Olsson SB
    Ital Heart J; 2004 May; 5(5):335-9. PubMed ID: 15185895
    [No Abstract]   [Full Text] [Related]  

  • 38. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study).
    Friberg L; Hammar N; Ringh M; Pettersson H; Rosenqvist M
    Eur Heart J; 2006 Aug; 27(16):1954-64. PubMed ID: 16847008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation.
    Ohara K; Inoue H; Nozawa T; Hirai T; Iwasa A; Okumura K; Lee JD; Shimizu A; Hayano M; Yano K
    Int J Cardiol; 2008 Jun; 126(3):316-21. PubMed ID: 17689760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal anticoagulation therapy in patients with valvular heart disease or atrial fibrillation.
    McLeod CJ; Gersh BJ
    Arch Intern Med; 2009 Nov; 169(21):2032-3; author reply 2033. PubMed ID: 19933968
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.